BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• Press Releases

  AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

  November 7, 2024

   · 

  4 min read
• Press Releases

  Radella Pharmaceuticals Announces Topline Data from the Phase 1a Study of MD-18, a First-In-Class Peptide Targeting PTP1B for Obesity

  November 7, 2024

   · 

  4 min read
• Press Releases

  Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting

  November 7, 2024

   · 

  4 min read
• Press Releases

  Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024

  November 7, 2024

   · 

  4 min read
• Press Releases

  SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting

  November 7, 2024

   · 

  2 min read
• Press Releases

  Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

  November 7, 2024

   · 

  5 min read
• Press Releases

  Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024

  November 7, 2024

   · 

  1 min read
• Press Releases

  Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

  November 7, 2024

   · 

  8 min read
• Press Releases

  Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer (SITC) Annual Conference

  November 7, 2024

   · 

  5 min read
• Press Releases

  Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

  November 7, 2024

   · 

  12 min read